Dr Andrew Epstein and Prof Richard Schilsky comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from the ASPECT trial.

This was a phase III randomised trial in which Barrett’s oesophagus patients at a high risk of developing high-grade dysplasia or oesophageal cancer were treated with high dose proton pump inhibitors and aspirin.

For more on these findings, watch Prof Jankowski present this data in the press conference here, watch Prof Jankowskis interview with ecancer here, or read news coverage here.